DeepMed Research

BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

Completed

Conditions: Chronic Kidney Disease
Type 2 Diabetes Mellitus

Interventions: Drug: Finerenone (Kerendia, BAY 948862)
Drug: Sodium-glucose cotransporter 2 inhibitors (SGLT2i)
Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
Drug: Steroidal mineral corticoid receptor antagonists (sMRA)
Drug: Non-steroidal mineral corticoid receptor antagonists (nsMRA)

First Posted Date: 2022-09-02

Last Posted Date: 2024-10-14

Lead Sponsor: Bayer

Target Recruit Count: 50000

Registration Number: NCT05526157

Locations: 🇪🇸
Many Locations, Multiple Locations, Spain
🇺🇸
Optum CDM, Eden Prairie, Minnesota, United States

Study on the Safety of the Drug BAY2395840 at Different Doses, the Way the Body Absorbs, Distributes and Excretes the Drug Including the Effect of Its Formulation (Tablet or Liquid) and the Effect of Food on the Absorption, Distribution or Excretion of the Drug in Healthy Male Participants

Phase 1

Completed

Conditions: Endometriosis

Interventions: Drug: BAY2395840 tablet
Drug: Placebo tablet
Drug: Placebo oral solution
Drug: BAY2395840 oral solution

First Posted Date: 2022-08-26

Last Posted Date: 2022-08-26

Lead Sponsor: Bayer

Target Recruit Count: 63

Registration Number: NCT05517746

Locations: 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight

Phase 1

Completed

Conditions: Healthy Volunteers
Chronic Kidney Disease
Renal Impairment

Interventions: Drug: Single oral dose of BAY3283142 IR (immediate release) tablet

First Posted Date: 2022-08-25

Last Posted Date: 2023-08-21

Lead Sponsor: Bayer

Target Recruit Count: 45

Registration Number: NCT05515432

Locations: 🇩🇪
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany

A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema

Phase 4

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

First Posted Date: 2022-08-22

Last Posted Date: 2025-04-15

Lead Sponsor: Bayer

Target Recruit Count: 100

Registration Number: NCT05511038

Locations: 🇮🇳
L.V. Prasad Eye Institute, Hyderabad, Andhra Pradesh, India
🇮🇳
Disha Eye Hospitals, Kolkata, West Bengal, India
🇮🇳
Sankara Eye Hospital, Bengaluru, Karnataka, India

and more 7 locations

A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses

Phase 1

Completed

Conditions: Hypertension
Chronic Kidney Disease

Interventions: Drug: BAY3283142
Drug: Placebo to BAY3283142

First Posted Date: 2022-08-08

Last Posted Date: 2023-05-17

Lead Sponsor: Bayer

Target Recruit Count: 56

Registration Number: NCT05491642

Locations: 🇧🇬
Medical Center Comac Medical EOOD, Sofia, Bulgaria
🇩🇪
Charité Research Organisation GmbH, Berlin, Germany
🇩🇪
CTC North GmbH & Co. KG, Hamburg, Germany

and more 1 locations

A Study to Learn How Well a Single Dose of the Study Treatment Naproxen Sodium and Caffeine Combined in One Tablet (Fixed-dose Combination) Works to Relieve Pain After Dental Surgeries Compared to the Single Ingredients and to Placebo

Phase 3

Completed

Conditions: Postoperative Dental Pain

Interventions: Drug: Naproxen sodium (Aleve)
Drug: Placebo
Drug: Naproxen sodium and caffeine (BAY2880376)
Drug: Caffeine

First Posted Date: 2022-08-03

Last Posted Date: 2025-03-25

Lead Sponsor: Bayer

Target Recruit Count: 541

Registration Number: NCT05485805

Locations: 🇺🇸
JBR Clinical Research, Salt Lake City, Utah, United States

A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants

Phase 1

Completed

Conditions: Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
Hot Flashes
Healthy Volunteers

Interventions: Drug: Elinzanetant (BAY3427080)
Drug: Moxifloxacin
Drug: Placebo

First Posted Date: 2022-08-01

Last Posted Date: 2023-05-09

Lead Sponsor: Bayer

Target Recruit Count: 51

Registration Number: NCT05481528

Locations: 🇩🇪
NUVISAN GmbH Neu-Ulm, Neu-Ulm, Bayern, Germany

An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health

Not yet recruiting

Conditions: Chagas Disease

Interventions: Drug: Nifurtimox (BAYA2502)

First Posted Date: 2022-07-28

Last Posted Date: 2025-04-30

Lead Sponsor: Bayer

Target Recruit Count: 50

Registration Number: NCT05477953

Locations: 🇭🇳
Many locations, Multiple Locations, Honduras
🇺🇾
Many Locations, Multiple Locations, Uruguay

A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment

Phase 4

Terminated

Conditions: Neovascular (Wet) Age-related Macular Degeneration

Interventions: Drug: Aflibercept(BAY86-5321, Eylea)

First Posted Date: 2022-07-26

Last Posted Date: 2024-10-16

Lead Sponsor: Bayer

Target Recruit Count: 3

Registration Number: NCT05473715

Locations: 🇬🇧
Bristol Eye Hospital, Bristol, United Kingdom
🇨🇦
GOGiunta ophtalmologie, Sherbrooke, Quebec, Canada
🇨🇦
Retina Center of Ottawa, Ottawa, Ontario, Canada

A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants

Phase 1

Completed

Conditions: Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
Hot Flashes
Healthy Volunteers

Interventions: Drug: Elinzanetant (BAY3427080)
Drug: Dabigatran etexilate

First Posted Date: 2022-07-25

Last Posted Date: 2022-11-22

Lead Sponsor: Bayer

Target Recruit Count: 20

Registration Number: NCT05471817

Locations: 🇩🇪
CRS Clinical Research Services Wuppertal GmbH, Wuppertal, Nordrhein-Westfalen, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy